Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2024 Oct 21;206(1):272–278. doi: 10.1111/bjh.19797

Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: A case series

Robert Galamaga 1,✉, Stephanie Johnston 1, Cassaundra Acosta 1
PMCID: PMC11739760  PMID: 39434457

Summary

Management of chemotherapy‐induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management. A phase III trial of avatrombopag (AVA) demonstrated increased platelet counts (PC) in patients with solid tumours experiencing CIT. To complement those findings, this case series of six patients with solid tumours and CIT is presented. Results from these cases support the clinical benefit of AVA in improving PC and reducing the impact of CIT on tumour treatment, allowing continued therapy without dose reduction or treatment interruption.

Keywords: avatrombopag, case series, chemotherapy‐induced thrombocytopenia, real‐world data, thrombopoietin receptor agonist

BACKGROUND

Chemotherapy‐induced thrombocytopenia (CIT) is a common complication of myelosuppressive chemotherapeutic regimens. 1 Platelet counts (PC) <100 × 109/L increase the risk of bleeding and cancer complications, leading to poor overall survival. 2 CIT management often involves chemotherapy treatment delays, dose reduction, and treatment interruption, reducing the relative dose intensity of treatment and leading to poor overall outcomes. 2

CIT management aims to reduce bleeding risk and the need for dose modifications and treatment interruption. 2 Recent guidelines provide recommendations for the use of thrombopoietin receptor agonists (TPO‐RAs) to manage CIT; however, further research is needed to better understand their benefits. 3

Both romiplostim and eltrombopag are reported to enhance PC in patients with CIT. 4 , 5 , 6 A phase III trial evaluating avatrombopag (AVA) in patients with severe CIT did not meet the primary composite end‐point, likely due to the rapid spontaneous recovery of PC in the placebo group. AVA was well tolerated and demonstrated a potential benefit in augmenting PC recovery. 7 This case series describes the treatment experience of six patients who developed CIT whilst undergoing chemotherapy and received treatment with AVA to manage CIT. AVA was selected for various reasons including lack of efficacy with previous CIT treatment, convenience, and cost. All patients in this case series received AVA under compassionate use investigational new drug authorization. A summary of each case is provided in Table 1.

TABLE 1.

Summary of clinical cases and avatrombopag dosing and efficacy.

Case No. Diagnosis Chemotherapy regimen AVA regimen and duration AVA efficacy
1 Advanced‐stage mucinous adenocarcinoma of the small bowel
  • C1–3: FOLFOX

  • C4–12: FOLFOX + BEV

  • AVA initiated at 20 mg q.d. at the start of C12

  • AVA duration: ~7 months

  • Patient required chemotherapy dose reductions due to CIT

  • Steroid therapy and eltrombopag treatment failed to improve CIT

  • AVA 20 mg q.d. improved PC to >100 × 109/L and chemotherapy dose was escalated to best tolerance

2 Primary cholangiocarcinoma
  • At the time CIT was observed: Gem/nab‐paclitaxel/Durva
  • AVA initiated at 20 mg q.d. 20 days prior to initiating C31

  • AVA increased to 40 q.d at C33

  • AVA duration: ~13 months

  • PC fluctuated whilst on AVA but chemotherapy was not held

3 Well‐ to moderately‐differentiated adenocarcinoma with mucinous features and a high probability of pancreaticobiliary origin
  • Gem/Cis/urva + TRA

  • AVA initiated at 20 mg q.d at C8D1

  • AVA increased to 40 q.d. at C9D8

  • AVA decreased to 10 mg q.d at C11D1

  • AVA increased to 40 mg q.d. between C12 and C13

  • AVA 20 mg and 40 mg alternating at C13D1

  • AVA 20 mg 1 day and 40 mg 6 days every 7 days at C14D15

  • AVA duration: ~8 months

  • AVA improved PC and was adjusted over time based on PC fluctuations

  • Following AVA initiation, CIT recurred and Gem/Cis treatment was held (C9D8) and AVA dose was increased, allowing to resume chemotherapy at the initial dose

  • PC fluctuated and chemotherapy and AVA doses were adjusted

  • Patient discontinued chemotherapy and was transferred to palliative care/hospice

4 Stage IIIC serous carcinoma of the endometrium
  • Doxil/Carbo/BEV D1, BEV D15

  • AVA 20 mg QD initiated between C1 and C2

  • AVA 40 mg q.d. between C2 and C3

  • AVA duration: ~8 months

  • AVA improved PC but CIT recurred following C13 BEV (D15) and treatment was held by 1 week but then resumed

  • There were no other chemotherapy holds or dose reductions due to CIT

5
  • FOLFOX

  • AVA 20 mg q.o.d. was initiated at C6

  • AVA was increased to 20 mg QD at C9

  • AVA duration: ~8 months

  • PC was improved following AVA initiation but dipped and was increased from q.o.d. to q.d. between C9 and C10

  • Following AVA initiation, there were no chemotherapy holds or dose reductions due to CIT

6
  • Enfortumab vedotin

  • AVA 20 mg q.o.d. was initiated at C2 and stopped ~8 months later (prescription ran out)

  • AVA 20 mg q.d. was initiated at C18

  • AVA duration: ~8 months, paused, then ~1 month

  • AVA improved PC and there were no chemotherapy holds or dose reductions due to CIT

  • Following discontinuation of AVA, the patient's PC decreased but improved after restarting AVA

Abbreviations: AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; CIT, chemotherapy‐induced thrombocytopenia; D, day; Doxil, doxorubicin; Durva, durvalumab; FOLFOX, 5‐folinic acid, fluorouracil, leucovorin, and oxaliplatin; Gem, gemcitabine; PC, platelet count; q.d., every day; q.o.d, every other day; TRA, trastuzumab.

CASE PRESENTATION

Clinical case 1: 70‐year‐old female diagnosed with advanced‐stage mucinous adenocarcinoma of the small bowel

The patient completed 12 cycles of 5‐folinic acid, fluorouracil, leucovorin, and oxaliplatin (FOLFOX). At treatment initiation, her PC was 167 × 109/L, which dropped to 67 × 109/L at cycle 3 (C3) (Figure 1A). Bevacizumab was added at C4, and the dose of the FOLFOX regimen was reduced due to severe thrombocytopenia, which had persisted for 20 days. Oral steroid therapy failed to improve her PC (63 × 109/L). Eltrombopag was initiated at 50 mg per day (QD). Her PC improved (150 × 109/L) after 4 weeks, but her thrombocytopenia recurred (70 × 109/L), requiring additional chemotherapy dose reduction (cycles 10 and 11). The eltrombopag dose was not increased and the patient was transitioned to AVA (20 mg QD) at the start of C12 given her lack of response to eltrombopag. Her PC gradually improved from 106 × 109/L to 175 × 109/L over 7 months. Chemotherapy dose was escalated to the best tolerance and adjusted based on the degree of thrombocytopenia. One adverse event (AE) of easy bruising was reported.

FIGURE 1.

FIGURE 1

Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5‐FU, 5‐fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5‐fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.

Clinical case 2: 53‐year‐old male with primary cholangiocarcinoma

Treatment was initiated with gemcitabine (1000 mg/m2) and cisplatin (20 mg/m2) every other week. Durvalumab (10 mg/kg) was added at C4. Nab‐paclitaxel (80 mg/m2) was added but discontinued ~1 month later due to side effects and the need for transfusions. At C14, cisplatin was discontinued due to an infusion reaction, and gemcitabine, nab‐paclitaxel, and durvalumab treatment were resumed. Radioembolization with yttrium‐90 microspheres to the right and left lobes was performed. Between C30 and C31, the patient's PC was 69 × 109/L; AVA (20 mg QD) was initiated 20 days prior to starting C31 (Figure 1B). His CIT persisted until cycle 33 (77 × 109/L) and AVA was increased to 40 mg QD. His PC increased to 180 × 109/L 22 days later but fluctuated over C34 through C38 (PC range, 40 × 109/L to 160 × 109/L). No AEs were reported.

Clinical case 3: 68‐year‐old male with well‐ to moderately‐differentiated adenocarcinoma with mucinous features and a high probability of pancreaticobiliary origin

The patient's treatment was initiated with gemcitabine (Day 1 [D1] and D8), cisplatin (D1 and D8) every 3 weeks, and durvalumab (D1) every 4 weeks; trastuzumab (D1) every 3 weeks was added following a HER2‐positive biopsy. At C7, his PC was 211 × 109/L but dropped to 38 × 109/L by C8 (Figure 1C). AVA 20 mg QD was initiated on D1C8. The patient's PC decreased to 33 × 109/L on C8D8 and chemotherapy was held. After ~3 weeks, the PC recovered to 174 × 109/L and chemotherapy was reinitiated (C9). On C9D8, the PC decreased to 82 × 109/L, and gemcitabine and cisplatin were held; AVA was increased to 40 mg QD. On C10D1, the patient's PC had recovered to 265 × 109/L and further increased to 300 × 109/L on C11D1. AVA was then decreased to 20 mg q.d. On C12D9, his PC decreased to 37 × 109/L and AVA was increased to 40 mg q.d. His PC recovered to 300 × 109/L on C13D1 and AVA was adjusted to 20 mg and 40 mg on alternating days. On C14D15 his PC was 42 × 109/L and AVA was adjusted to 20 mg q.d. for 1 day and 40 mg q.d. for 6 days each week. On C15D1, the patient's PC decreased to 42 × 109/L and the chemotherapy regimen was adjusted (cisplatin dose reduction, gemcitabine held). On C15D15, his PC had recovered to 219 × 109/L and the initial chemotherapy regimen was reinstated. The patient's PC was reduced to 40 × 109/L on C16D1 and the gemcitabine and cisplatin doses were reduced. The patient's PC remained below 100 × 109/L and the chemotherapy regimen was adjusted accordingly until chemotherapy was discontinued following the completion of C17. The patient was then transferred to palliative care/hospice (PC, 71 × 109/L at the time of transfer). No AEs were reported.

Clinical case 4: 42‐year‐old female with stage IIIC serous carcinoma of the endometrium

The patient was initially treated with 5 cycles of carboplatin/paclitaxel and then underwent bilateral salpingo‐oophorectomy and lymph node excision, which showed synchronous primary tumours of the ovary and uterus. Bevacizumab was added to her treatment regimen during C7 and C8, and she had radiation therapy 4500 cGy to the pelvis and peri‐aortic lymph node followed by 1500 cGy to the vaginal apex. She received maintenance therapy with niraparib 200 mg q.d. and 6 cycles of doxorubicin HCl liposome injection/carboplatin plus bevacizumab (doxil + carbo + bev). At the beginning of doxil + carbo + bev treatment, the patient's PC was 167 × 109/L but dropped to 69 × 109/L and 48 × 109/L during C1 (Figure 1D). Treatment with AVA 20 mg QD was initiated ~2 weeks prior to starting C2; on C2D1 her PC was 194 × 109/L but decreased to 100 × 109/L on C2D15. AVA was increased to 40 mg q.d on C2D21. The patient's PC generally remained below 100 × 109/L through the completion of C6 at which time the patient received intraperitoneal low‐dose gemcitabine plus cisplatin followed by maintenance cisplatin therapy. Throughout chemotherapy treatment, mild thrombocytopenia was allowed and both chemotherapy and AVA treatment were continued with curative intent. No AEs were reported.

Clinical case 5: 71‐year‐old male with metastatic pancreatic ductal adenocarcinoma

The patient received gemcitabine plus nab‐paclitaxel for ~2 months followed by irinotecan liposome injection in combination with 5‐fluorouracil for ~1 month. He then started treatment with FOLFOX for 3 months, followed by the transition to 5‐fluorouracil, leucovorin, and irinotecan (FOLFIRI) was added ~3 months later.

At FOLFOX treatment C1, the patient's PC was 129 × 109/L then dropped to 76 × 109/L following C3, and his treatment was paused and then reinitiated following an increase in PC to 96 × 109/L (Figure 1E). At C6, the patient's PC dropped to 89 × 109/L and AVA 20 mg every other day was initiated. Irinotecan was added to the chemotherapy regimen at C7. Between C9 and C10, the patient's PC dropped to 79 × 109/L and AVA was increased to 20 mg q.d. The PC increased to 142 × 109/L at C10 and remained >100 × 109/L through C14 (end of treatment). No AEs were reported.

Clinical case 6: 65‐year‐old female with stage IV advanced bladder cancer

The patient was treated with enfortumab vedotin but experienced major issues with dermatologic toxicity resulting in dose reduction. Persistent thrombocytopenia (PC 71 × 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F). Her PC improved to 226 × 109/L after 1 month. Approximately 7.5 months later, the patient stopped taking AVA as her prescription ran out and 21 days later her PC dropped to 81 × 109/L. She restarted AVA 20 mg q.d 7 days later and her PC recovered to 208 × 109/L within a month. No chemotherapy dose reductions were needed. No AEs were reported.

DISCUSSION AND CONCLUSIONS

CIT is a severe complication of myelosuppressive chemotherapy that can impede optimal treatment. Treatment interruptions may lead to undesirable outcomes whilst contributing to patient distress. Maintaining an optimal relative dose intensity of cancer therapy is critical to achieving desired treatment outcomes. 1 For example, Tannock et al. reported that reducing the dose intensity of cyclophosphamide/methotrexate/5‐fluorouracil by 50% reduced the incidence of thrombocytopenia but significantly decreased median survival. 8

This case series, which included a variety of patients with solid tumours receiving intensive chemotherapy regimens, demonstrated the utility of AVA in treating CIT and improving PC. No platelet transfusions were needed and PC stabilization allowed for anticancer therapy continuation. AVA was well tolerated, with no bleeding or thromboembolic events whilst on AVA. These findings support those of the phase III clinical trial that demonstrated the safety of AVA in augmenting PC in patients with CIT 7 ; however, this case series is limited by the small number of patients. Larger studies are needed to fully investigate the efficacy of AVA for CIT. This case series provides evidence to help support clinical decision‐making when treating oncology patients who develop CIT.

AUTHOR CONTRIBUTIONS

Robert Galamaga designed the study, collected and interpreted the data, and wrote the report. Stephanie Johnston and Cassaundra Acosta collected the data. All authors critically reviewed and approved the report.

FUNDING INFORMATION

Medical writing support was provided by Yasser Heakal, PhD, and Sarah Bubeck, PhD, of BioCentric, Inc. (Collingswood, NJ), and funded by Sobi Inc. (Durham, NC).

CONFLICT OF INTEREST STATEMENT

Robert Galamaga has received consulting fees from Sobi Inc. for non‐branded speaking engagements. Stephanie Johnston and Cassaundra Acosta have no conflicts of interest to declare.

ETHICAL APPROVAL STATEMENT

As this was a case series, ethical approval was not required.

PATIENT CONSENT STATEMENT

Identifying details have been omitted from this manuscript; therefore, patient consent was not required.

Galamaga R, Johnston S, Acosta C. Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: A case series. Br J Haematol. 2025;206(1):272–278. 10.1111/bjh.19797

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

  • 1. Kuter DJ. Treatment of chemotherapy‐induced thrombocytopenia in patients with non‐hematologic malignancies. Haematologica. 2022;107(6):1243–1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Gao A, Zhang L, Zhong D. Chemotherapy‐induced thrombocytopenia: literature review. Discov Oncol. 2023;14(1):10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Soff G, Leader A, Al‐Samkari H, Falanga A, Maraveyas A, Sanfilippo K, et al. Management of chemotherapy‐induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy. J Thromb Haemost. 2024;22(1):53–60. [DOI] [PubMed] [Google Scholar]
  • 4. Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, et al. Romiplostim treatment of chemotherapy‐induced thrombocytopenia. J Clin Oncol. 2019;37(31):2892–2898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Winer ES, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine‐based chemotherapy: a randomized, placebo‐controlled phase 2 study. Int J Hematol. 2017;106(6):765–776. [DOI] [PubMed] [Google Scholar]
  • 6. Zhu Q, Yang S, Zeng W, Li M, Guan Z, Zhou L, et al. A real‐world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia. Front Oncol. 2021;11:701539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Al‐Samkari H, Kolb‐Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy‐induced thrombocytopenia in patients with non‐haematological malignancies: an international, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Haematol. 2022;9(3):e179–e189. [DOI] [PubMed] [Google Scholar]
  • 8. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988;6(9):1377–1387. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from British Journal of Haematology are provided here courtesy of Wiley

RESOURCES